Jennifer Rup1, Tom P Freeman2, Chris Perlman1, David Hammond3. 1. School of Public Health & Health Systems, University of Waterloo, ON N2L 3G1, Canada. 2. Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath BA2 7AY, United Kingdom. 3. School of Public Health & Health Systems, University of Waterloo, ON N2L 3G1, Canada. Electronic address: david.hammond@uwaterloo.ca.
Abstract
BACKGROUND: Cannabis can have an adverse impact on some mental health conditions, while many consumers report using cannabis to manage or improve mental health. Little data exists on how patterns of cannabis use differ by mental health status. The current study examined the prevalence of cannabis use and modes of cannabis administration among consumers who experienced a mental health condition in the past 12-months. METHODS: Data came from the International Cannabis Policy Study (Wave 1). Online surveys were conducted from Aug - Oct 2018 with 25,747 respondents aged 16-65, recruited from commercial panels in Canada and the US. Multinomial and binary regression models examined differences in cannabis prevalence and use of nine cannabis product types among those with and without self-reported past 12-month experience of anxiety, depression, PTSD, bipolar disorder, and psychosis. RESULTS: Respondents with each of the five mental health conditions reported more frequent cannabis use than those without a mental health condition (p < .01). Past 12-month cannabis consumers who experienced mental health conditions were significantly more likely to use the most potent products (solid concentrates, THC vape oils, hash) (p < .05), with fewer differences for dried flower, edibles, and other forms. Patterns of use were similar across specific mental health conditions, with some differences among respondents reporting psychosis and bipolar disorder. CONCLUSION: Individuals experiencing mental health conditions report more frequent cannabis use and use of more potent product types. These findings highlight the need to target use of specific high potency products in prevention, treatment, and harm reduction among these populations.
BACKGROUND: Cannabis can have an adverse impact on some mental health conditions, while many consumers report using cannabis to manage or improve mental health. Little data exists on how patterns of cannabis use differ by mental health status. The current study examined the prevalence of cannabis use and modes of cannabis administration among consumers who experienced a mental health condition in the past 12-months. METHODS: Data came from the International Cannabis Policy Study (Wave 1). Online surveys were conducted from Aug - Oct 2018 with 25,747 respondents aged 16-65, recruited from commercial panels in Canada and the US. Multinomial and binary regression models examined differences in cannabis prevalence and use of nine cannabis product types among those with and without self-reported past 12-month experience of anxiety, depression, PTSD, bipolar disorder, and psychosis. RESULTS: Respondents with each of the five mental health conditions reported more frequent cannabis use than those without a mental health condition (p < .01). Past 12-month cannabis consumers who experienced mental health conditions were significantly more likely to use the most potent products (solid concentrates, THC vape oils, hash) (p < .05), with fewer differences for dried flower, edibles, and other forms. Patterns of use were similar across specific mental health conditions, with some differences among respondents reporting psychosis and bipolar disorder. CONCLUSION: Individuals experiencing mental health conditions report more frequent cannabis use and use of more potent product types. These findings highlight the need to target use of specific high potency products in prevention, treatment, and harm reduction among these populations.
Authors: Danielle C Ompad; Kyle M Snyder; Simon Sandh; Daniel Hagen; Kewanda J Collier; Emily Goldmann; Melody S Goodman; Andy S L Tan Journal: Drug Alcohol Depend Date: 2022-03-15 Impact factor: 4.852